La Jolla Pharmaceutical Co banner
L

La Jolla Pharmaceutical Co
F:LJPP

Watchlist Manager
La Jolla Pharmaceutical Co
F:LJPP
Watchlist
Price: 6.072 EUR Market Closed
Market Cap: €151.2m

La Jolla Pharmaceutical Co
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

La Jolla Pharmaceutical Co
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
L
La Jolla Pharmaceutical Co
F:LJPP
Other Items
$271k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Items
-$5.4B
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Other Items
-$4.2B
CAGR 3-Years
-35%
CAGR 5-Years
21%
CAGR 10-Years
10%
Amgen Inc
NASDAQ:AMGN
Other Items
-$85m
CAGR 3-Years
74%
CAGR 5-Years
55%
CAGR 10-Years
33%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Items
-$507.8m
CAGR 3-Years
-63%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Items
$584.6m
CAGR 3-Years
N/A
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

La Jolla Pharmaceutical Co
Glance View

Market Cap
151.2m EUR
Industry
Biotechnology

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.

LJPP Intrinsic Value
Not Available
L

See Also

What is La Jolla Pharmaceutical Co's Other Items?
Other Items
271k USD

Based on the financial report for Jun 30, 2022, La Jolla Pharmaceutical Co's Other Items amounts to 271k USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett